This study in north east Scotland has shown that Marfan syndrome has a minimal birth incidence of 1:9802 live births, a minimal prevalence of 1:14217, and that 8/30 (26-7%) of cases in our series are new mutations. The calculated mutation rate is 15±6-7 x 10-6 and there is evidence of reduced reproductive fitness.
The connective tissue disorder Marfan syndrome was described for the first time in 1896' and then defined over the next 50 years as a genetically inherited, autosomal dominant disorder of near complete penetrance but wide variability in clinical expression. The classical syndrome consists of abnormalities in the cardiovascular, skeletal, and ocular systems, the cardiovascular features being responsible for the significant mortality. Lynas2 performed the only previous population study of Marfan syndrome in 1958. Although a very detailed study for the time, it was recognised by the author that the prevalence figure of 1-459 per 100 000 population (and equally the given mutation rate of between 4-2 and 5-8 x 10-6 per generation) was certain to be an underestimate. In more recent times the prevalence figure has been estimated at between 4 and 6 per 100 0003 climbing to the widely quoted 1 in 10 0004 with no differences detected in any racial or ethnic group or indeed any difference between males and females. This study set out to determine the prevalence of Marfan Two clinicians (JRG and ABB) evaluated all patients with reference to the diagnostic criteria laid out in the Berlin Nosology.6 A family history was taken and all patients received a physical examination.
Skeletal evaluation
Various skeletal indices were measured. Dolichostenomelia was assessed partly on a subjective scale and partly as a function of span being at least 7-5 cm greater than height,7 and an upper segment to lower segment ratio less than 0 85 was regarded as abnormal.
Ophthalmology Slit lamp and fundal examination, through dilated pupils, were performed by one ophthalmologist familiar with Marfan syndrome. Myopia was marked as positive if severe (greater than 6 diopters).
Echocardiography
All echocardiograms were performed by the same cardiologist familiar with Marfan syndrome. Recordings were made using a Hewlett Packard Sonus 1000. The following indices were determined: (1) aortic diameter, assessed by M mode, was considered increased in adults when greater than 37 mm and in patients under 16 years of age it was related to body surface area8; (2) identified giving no family history of Marfan syndrome in their sibs or in preceding generations. In three cases both parents were clinically assessed and in a further three cases the parents were not seen but hospital and general practitioner notes were examined. In two cases information on the parents was obtained from other family members. All eight cases were assumed to be new mutations of the Marfan syndrome gene. Four of these subjects currently have children, two of eight offspring being affected.
DISEASE PREVALENCE
To take account of this, the ratio of new mutations to familial cases at different ages was compared. One of 10 cases (10%) aged less than 20 years was a new mutation, compared with four of 20 (20%) cases aged 20 years or over. This implies that one new mutation aged less than 20 years was undetected, and correcting for this gives a prevalence of 1:14217 or 7 03 per 100 000.
INCIDENCE
The birth incidence of 1:9802 live births was estimated from the point prevalence of affected subjects who would have been aged between 15 and 39 on prevalence day (including two dead subjects), in comparison with the total population aged between 15 Estimated mutation rate'0 (g ± 95% confidence interval) was 5/2 x 166 641 = 15 x 10-6, standard error= >/pq/2N= 6-7 x 106. The mutation rate is 15 ± 6-7 x 10-6.
ESTIMATION OF FITNESS IN MARFAN SYNDROME
Estimation of fitness analysis'01' was performed using the 13 Segregation analysis is consistent with the expected autosomal dominant single gene mode of transmission. In only one family was there evidence of an affected subject with an apparently normal but transmitting parent.
The calculated incidence of the disorder is 1 in 9802. The discrepancy between this figure and the prevalence rate may reflect childhood mortality. Previous studies'2 13 have shown mortality and significant cardiac morbidity in infants and children afflicted with Marfan syndrome.
Marfan syndrome may cause death or severe handicap throughout adulthood and it may be anticipated to reduce reproductive fitness. We calculated a reproductive fitness of 0-647. There was no evidence of infertility in any of the couples in our study and we feel social factors such as voluntary family limitation may play a major part in reducing reproductive fitness, especially where a family has experienced severe manifestations of the condition. We are unaware of any similar studies on this disorder with which to compare this result.
The potential ascertainment difficulties have been mentioned, yet the estimate of mutation rate, at between 15+6-7x 10-6 and 18 ± 7.3 x 10-6 per haploid genome per generation is of the same order as estimated for tuberous sclerosis (2-5 x 10-5)'4 and neurofibromatosis type 1 (3-1 to 1O-4 x 1O-')' and greater than other dominant disorders such as Apert's syndrome (3 x 10-6).16 Our estimate for the mutation rate is greater than that calculated by Lynas for the population of Northern Ireland (between 4.2 and 5-8 x 106), perhaps because of more complete ascertainment. The combination of the reduced reproductive fitness and the relatively high incidence of the disorder suggests that our higher mutation rate is likely to be in the correct range.
Eight of 30 cases in the prevalence study group are assumed to be new mutations. This figure agrees with other widely quoted estimates of between 25% and 35% of cases.4 Parental ages are given in table 1 and there is no evidence of an advanced paternal age effect as described by other workers.'7 This may reflect our small sample size and continuing international studies using the current diagnostic criteria will be invaluable in addressing this question.
The severity of cardiovascular and skeletal components of the disorder was assessed using graded scales. Cardiovascular and skeletal features showed no significant differences in severity when analysed according to sex, parental origin of the affected allele, or whether the cases were familial or new mutations. At present there are insufficient cases to address any suggestion that gene modification by imprinting could be involved in Marfan syndrome. This study provides preliminary data that will be useful in genetic counselling, there being no evidence for a more severe phenotype in either sex or evidence of maternal imprinting. The calculated incidence and prevalence figures, which are 10 times greater than previously reported for European populations, will allow assessment of the appropriate allocation of resources to this potentially fatal disease.
